Bli medlem
Bli medlem

Du är här

2016-05-10

BioGaia: BioGaia AB - Interim management statement 1 January - 31 March 2016

Comments from the Managing Director:

"Compared to the same period of last year, the first quarter of 2016
showed a varied palette of sales successes in Canada and the USA,
modest development in Europe and declining sales in Asia and Rest of
World. The highlights included the successful launch of our new Easy
Dropper, which will eventually replace the glass bottles for our
drops, and two meta-analyses that confirm the effectiveness of
BioGaia ProTectis in colic and the effectiveness of BioGaia ProDentis
in periodontitis. At the end of the period we distributed the shares
in IBT to our shareholders, and since that time IBT is an independent
company that is listed on Nasdaq First North," says Axel Sjöblad,
Managing Director of BioGaia AB.

Period from 1 January - 31 March 2016
(Figures in brackets refer to the same period of last year. The
comparative figures in the balance sheet refer to 31 December 2015.)

· Net sales amounted to SEK 133.9 million (138.8), a decrease of SEK
4.9 million (4%).

· Net sales in the Paediatrics business area reached SEK 108.1
million (115.3)¹, a decrease of SEK 7.2 million (6%).

· Net sales in the Adult Health business area amounted to SEK 21.1
million (19.8), an increase of SEK 1.3 million (7%).

· Operating profit was SEK 46.1 million (52.6), a decrease of SEK
6.5 million (12%). Excluding expenses in the former subsidiary IBT,
operating profit was SEK 51.3 million (56.3).

· Profit after tax was SEK 33.6 million (43.2), a decrease of SEK
9.6 million (22%).

· Earnings per share totalled SEK 1.95 (2.50).
· The period's cash flow was SEK -4.8 million (37.8). Cash and cash
equivalents at 31 March 2016 amounted to SEK 221.5 million (226.9).
BioGaia's former subsidiary IBT was distributed to BioGaia's
shareholders on 29 March 2016. Excluding IBT, the period's cash flow
was SEK 39.0 million.

Key events in the first quarter of 2016

· BioGaia distributed the shares in IBT on 29 March 2016 in
accordance with the resolution of the extraordinary general meeting.

· New meta-analysis confirms the effectiveness of BioGaia ProTectis
in colic.

· Meta-analysis confirms the effectiveness of BioGaia ProDentis in
periodontal disease.

Key events after the end of the first quarter

· Agreement for the sale of BioGaia ProDentis in Hong Kong.
· BioGaia guarantees rights issue in IBT.
· Yet another meta-analysis confirms the effectiveness of BioGaia
ProTectis in colic.

1) A minor reallocation between the segments was made in the previous
year's sales in order to achieve better comparability with the year's
figures.

Teleconference: You are welcome to take part in a teleconference on
the interim management statement that will be held today at 9:30 a.m.
by Managing Director Axel Sjöblad. To participate in the
teleconference please see www.biogaia.com/agenda. You can also follow
the presentation at http://financialhearings.nu/?160510/biogaia.

BioGaia has published this information in accordance with the Swedish
Securities Act. The information was issued for publication on 10 May
2016, 8.00 a.m.

This is a translation of the Swedish version of the interim report.
When in doubt, the Swedish wording shall prevail.

Latest press releases from BioGaia:
2016-05-02 Yet another meta-analysis confirms the effectiveness of
BioGaia's probiotic in infantile colic

2016-04-27 BioGaia guarantees rights issue in IBT
2016-04-27 IBT's results for the first quarter of 2016
For additional information contact:
Axel Sjöblad, Managing Director, BioGaia AB, telephone 46 8-555 293 00
or Margareta Hagman, Executive Vice President, BioGaia AB, telephone
46 8-555 293 00

BioGaia is a healthcare company that develops, markets and sells
probiotic products with documented health benefits. The products are
primarily based on the lactic acid bacterium Lactobacillus reuteri,
which has probiotic, health-enhancing effects. The class B share of
the Parent Company BioGaia AB is quoted on the Mid Cap list of the
NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com

-----------------------------------------------------------
http://news.cision.com/biogaia/r/biogaia-ab---interim-management-stateme...
http://mb.cision.com/Main/3271/2005547/513359.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.